Perjeta (Pertuzumab) Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Description

Perjeta (pertuzumab) is a targeted therapy used in the treatment of specific types of breast cancer. It is a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2), a protein that accelerates the growth of cancer cells in HER2-positive breast cancer.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary types of perjeta (pertuzumab) are human source and animal source. While Perjeta is a monoclonal antibody developed through recombinant DNA technology and produced using mammalian cell lines, animal-derived components may be used in the production process. It includes products like monoclonal antibodies and biologic drugs, with indications for conditions such as early-stage and metastatic breast cancer. Perjeta is distributed through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The perjeta (pertuzumab) market research report is one of a series of new reports from The Business Research Company that provides perjeta (pertuzumab) market statistics, including perjeta (pertuzumab) industry global market size, regional shares, competitors with a perjeta (pertuzumab) market share, detailed perjeta (pertuzumab) market segments, market trends and opportunities, and any further data you may need to thrive in the perjeta (pertuzumab) industry. This perjeta (pertuzumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The perjeta (pertuzumab) market size is expected to see rapid growth in the next few years. It will grow to $1,932.7 million in 2029 at a compound annual growth rate (CAGR) of 16%. The growth in the forecast period can be attributed to the rising incidence of breast cancer, rising interest in ADCs for hematologic malignancies, rising incidence of cancer, rising cancer incidence and unmet medical needs, and increasing pharmaceutical R&D for cancer immunotherapy. Major trends in the forecast period include the adoption of biosimilars in oncology, the development of biosimilars and generics, innovation in drug formulations, advances in cancer immunotherapy research, and combination therapies gaining prominence.

The rising incidence of breast cancer is expected to drive the growth of the perjeta (pertuzumab) market. Breast cancer is a disease where malignant cells develop in breast tissue, often originating in the ducts or lobules. The increase in breast cancer cases is attributed to factors like lifestyle changes, such as higher obesity rates and sedentary habits, along with improvements in early detection through widespread screening programs. Perjeta (pertuzumab) is used to treat HER2-positive breast cancer by targeting the HER2 receptor and is typically combined with trastuzumab and chemotherapy for enhanced treatment outcomes. For example, in October 2023, the Ray of Light Wales, a UK-based charity, reported that the number of people living after a breast cancer diagnosis in the UK is projected to double from 600,000 in 2023 to 1.2 million by 2030. Therefore, the rising incidence of breast cancer is driving the growth of the perjeta market.

A key trend in the perjeta (pertuzumab) market is the focus on developing technologically advanced solutions, such as subcutaneous combination therapies, to improve patient outcomes and treatment convenience. Subcutaneous combination therapies involve the combination of two or more drugs in a single subcutaneous injection to treat a specific condition. In November 2023, Chugai Pharmaceutical Co., Ltd., a Japan-based pharmaceutical company, launched Phesgo, a subcutaneous combination treatment for HER2-positive breast cancer and advanced or recurrent HER2-positive colorectal cancer. This innovative treatment combines pertuzumab and trastuzumab with vorhyaluronidase alfa, allowing administration in just 5 to 8 minutes, significantly reducing time compared to traditional intravenous infusions. Phesgo is the first subcutaneous option for HER2-positive colorectal cancer, marking a major advancement in treatment delivery.

In June 2024, Zydus Pharmaceuticals, an India-based company, partnered with Dr. Reddy's Laboratories to enhance access to a pertuzumab biosimilar for HER2-positive breast cancer patients in India. This collaboration aims to improve the affordability, availability, and patient outcomes by leveraging their combined distribution efforts. Dr. Reddy's Laboratories, a key player in the Indian pharmaceutical sector, offers pertuzumab biosimilars, making this partnership a significant step toward increasing the accessibility of this treatment in the region.

Key player operating in the perjeta (pertuzumab) market is Roche Holding AG.

North America was the largest region in the perjeta (pertuzumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in perjeta (pertuzumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the perjeta (pertuzumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The perjeta (pertuzumab) market consists of sales of products including herceptin, docetaxel, paclitaxel, and carboplatin. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Perjeta (Pertuzumab) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on perjeta (pertuzumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 10 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 3-4 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for perjeta (pertuzumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The perjeta (pertuzumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Human source; Animal source
2) By Product: Monoclonal Antibody; Biologic Drug
3) By Indication: Early Breast Cancer; Metastatic Breast Cancer
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Companies Mentioned: Roche Holding AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r33104

1. Executive Summary

2. Perjeta (Pertuzumab) Market Characteristics

3. Perjeta (Pertuzumab) Market Biologic Drug Characteristics

3.1. Molecule Type
3.2. Route Of Administration (ROA)
3.3. Mechanism Of Action (MOA)
3.4. Safety And Efficacy

4. Perjeta (Pertuzumab) Market Trends And Strategies

5. Perjeta (Pertuzumab) Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

6. Global Perjeta (Pertuzumab) Growth Analysis And Strategic Analysis Framework

6.1. Global Perjeta (Pertuzumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis Of End Use Industries
6.3. Global Perjeta (Pertuzumab) Market Growth Rate Analysis
6.4. Global Perjeta (Pertuzumab) Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
6.5. Global Perjeta (Pertuzumab) Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
6.6. Global Perjeta (Pertuzumab) Total Addressable Market (TAM)

7. Global Perjeta (Pertuzumab) Market Pricing Analysis & Forecasts

8. Perjeta (Pertuzumab) Market Segmentation

8.1. Global Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Human source
Animal source
8.2. Global Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibody
Biologic Drug
8.3. Global Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Early Breast Cancer
Metastatic Breast Cancer
8.4. Global Perjeta (Pertuzumab) Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

9. Global Perjeta (Pertuzumab) Market Epidemiology Of Clinical Indications

9.1. Drug Side Effects
9.2. Incidence And Prevalence of Clinical Indications

10. Perjeta (Pertuzumab) Market Regional And Country Analysis

10.1. Global Perjeta (Pertuzumab) Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Perjeta (Pertuzumab) Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Asia-Pacific Perjeta (Pertuzumab) Market

11.1. Asia-Pacific Perjeta (Pertuzumab) Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Asia-Pacific Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Asia-Pacific Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. China Perjeta (Pertuzumab) Market

12.1. China Perjeta (Pertuzumab) Market Overview
12.2. China Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.3. China Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
12.4. China Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

13. India Perjeta (Pertuzumab) Market

13.1. India Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. India Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. India Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. Japan Perjeta (Pertuzumab) Market

14.1. Japan Perjeta (Pertuzumab) Market Overview
14.2. Japan Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. Japan Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. Japan Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Australia Perjeta (Pertuzumab) Market

15.1. Australia Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.2. Australia Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Australia Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. South Korea Perjeta (Pertuzumab) Market

16.1. South Korea Perjeta (Pertuzumab) Market Overview
16.2. South Korea Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. South Korea Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.4. South Korea Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Western Europe Perjeta (Pertuzumab) Market

17.1. Western Europe Perjeta (Pertuzumab) Market Overview
17.2. Western Europe Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Western Europe Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.4. Western Europe Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. UK Perjeta (Pertuzumab) Market

18.1. UK Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. UK Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. UK Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Germany Perjeta (Pertuzumab) Market

19.1. Germany Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Germany Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Germany Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. France Perjeta (Pertuzumab) Market

20.1. France Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. France Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. France Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Perjeta (Pertuzumab) Market

21.1. Eastern Europe Perjeta (Pertuzumab) Market Overview
21.2. Eastern Europe Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. North America Perjeta (Pertuzumab) Market

22.1. North America Perjeta (Pertuzumab) Market Overview
22.2. North America Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. North America Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.4. North America Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. USA Perjeta (Pertuzumab) Market

23.1. USA Perjeta (Pertuzumab) Market Overview
23.2. USA Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. USA Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. USA Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. Canada Perjeta (Pertuzumab) Market

24.1. Canada Perjeta (Pertuzumab) Market Overview
24.2. Canada Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. Canada Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. Canada Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. South America Perjeta (Pertuzumab) Market

25.1. South America Perjeta (Pertuzumab) Market Overview
25.2. South America Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. South America Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. South America Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. Middle East Perjeta (Pertuzumab) Market

26.1. Middle East Perjeta (Pertuzumab) Market Overview
26.2. Middle East Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. Middle East Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. Middle East Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Africa Perjeta (Pertuzumab) Market

27.1. Africa Perjeta (Pertuzumab) Market Overview
27.2. Africa Perjeta (Pertuzumab) Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Africa Perjeta (Pertuzumab) Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.4. Africa Perjeta (Pertuzumab) Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Perjeta (Pertuzumab) Market Competitive Landscape And Company Profiles

28.1. Perjeta (Pertuzumab) Market Competitive Landscape
28.2. Perjeta (Pertuzumab) Market Company Profiles
- 28.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

29. Global Perjeta (Pertuzumab) Market Pipeline Analysis

29.1. High Level Clinic Trail Information

30. Global Perjeta (Pertuzumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Perjeta (Pertuzumab) Market

32. Recent Developments In The Perjeta (Pertuzumab) Market

33. Perjeta (Pertuzumab) Market High Potential Countries, Segments and Strategies

33.1 Perjeta (Pertuzumab) Market In 2029 - Countries Offering Most New Opportunities
33.2 Perjeta (Pertuzumab) Market In 2029 - Segments Offering Most New Opportunities
33.3 Perjeta (Pertuzumab) Market In 2029 - Growth Strategies
- 33.3.1 Market Trend Based Strategies
- 33.3.2 Competitor Strategies

34. Appendix

34.1. Abbreviations
34.2. Currencies
34.3. Historic And Forecast Inflation Rates
34.4. Research Inquiries
34.5. The Business Research Company
34.6. Copyright And Disclaimer